AbbVie (ABBV) Tops Q4 EPS by 6c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Abbvie (ABBV) PT Raised to $135 at RBC Capital
February 4, 2021 7:00 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Abbvie (NYSE: ABBV) to $135.00 (from $129.00) while maintaining a Outperform rating. Overall, the outlook feels stable and very notably to Stanicky like a clear contrast to large cap biopharma peers dealing with mid-2020's... More
